(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 78.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Sangamo Therapeutics's revenue in 2026 is $39,552,000.On average, 7 Wall Street analysts forecast SGMO's revenue for 2026 to be $20,392,638,487, with the lowest SGMO revenue forecast at $3,491,501,415, and the highest SGMO revenue forecast at $49,588,599,835. On average, 6 Wall Street analysts forecast SGMO's revenue for 2027 to be $69,863,170,227, with the lowest SGMO revenue forecast at $28,743,988,396, and the highest SGMO revenue forecast at $113,792,786,990.
In 2028, SGMO is forecast to generate $87,552,670,753 in revenue, with the lowest revenue forecast at $8,119,770,733 and the highest revenue forecast at $184,869,780,086.